Скачать или смотреть IgA Nephropathy Game-Changer Drug Explained : Filspari (Sparsentan) vs ARBs | Positive Update

📢 IgA Nephropathy Update for 2025!
In this exclusive video, Dr. Shoeb Khan speaks with a patient who was treated with Filspari (Sparsentan) in the USA—a breakthrough drug in the management of IgA Nephropathy (IgAN).

Now back in India, the patient must shift to a regular ARB, and Dr. Shoeb explains why Filspari is a game-changer and how it works differently and more effectively than traditional ARBs.

🧠 In this video, you'll learn:

Latest updates on IgA Nephropathy treatment

How Filspari (Sparsentan) works: Dual action on ETAR and AT1R

Why it’s more effective than standard ARBs in reducing proteinuria

The hope for availability of this drug in India soon

Real-world discussion with a patient who has used it

💊 As global nephrology moves toward precision medicine, Filspari marks a major step forward in IgAN care.

✅ Good News for Indian Patients: Momentum is building, and we remain optimistic that Filspari will soon be accessible in India, bringing world-class treatment to more patients.

🔔 Stay updated on IgA Nephropathy breakthroughs. Like, Share & Subscribe for weekly nephrology insights!

#IgANephropathy #Filspari #Sparsentan #KidneyUpdates #DrShoebKhan #Nephrology2025 #Proteinuria #ARBs #KidneyCareIndia #SAPKidneyCenter #IgANIndia #KidneyWarrior #NephrologyNews